Author + information
The metabolic syndrome (MS) is a cluster of metabolic perturbations largely resulting from an excess accumulation of abdominal fat, and it is characterized by insulin resistance, hypertriglyceridemia, low high-density lipoprotein cholesterol, and the presence of small dense low-density lipoprotein particles and it has been shown to result in a dramatic increase of type 2 diabetes and cardiovascular disease (CVD). The aim of this study was to assess the impact of metabolic syndrome on the clinical outcomes after coronary artery stenting.
We have investigated 132 patients (m=61; mean age 61.4 years old) who have undergone coronary artery stenting with MS compared to the subjects without MS (control group; n=52; m=27; mean age 61.8 years old) during the 3 years (mean follow-up 2.8 years). Metabolic syndrome was defined by the “Harmonized” definition of the MS.
Patients who have had metabolic syndrome were associated with a significant restenosis (odd ratio (OR) 1.29, Confidential Interval (CI) 95%, 0.98-1.76) and adverse cardiac events (OR 1.28; CI 95%, 0.98-1.71) than those of patients without of this syndrome (restenosis: OR 1.10; CI 95%, 0.96-1.42; adverse cardiac events: OR 1.12; CI 95%, 0.99-1.52; p<0.05).
After stent implantation, metabolic syndrome is an important risk factor for adverse cardiac events and restenosis rate in patients with coronary artery disease.